Deep Track Capital, LP: IMMUNOVANT INC (IMVT): Quarterly 13F Position History
As of Q1 2026, Deep Track Capital, LP reported 11,526,971 shares of IMMUNOVANT INC (IMVT), worth $286.3M and representing 5.9% of its 13F equity book. The position first appeared in Q4 2021 and has been disclosed across 18 13F-HR filings in Pactolio's tracked window.
- 11,526,971Shares Held (Latest Filing)
- $286.3MReported Market Value (Latest Filing)
- 5.9%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$6.7MQuarter-over-Quarter Value Change
- 11,526,971Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 18 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 11,526,971 | 0 | — | $286.3M | 5.9% | $24.8 |
| Q4 2025 | 11,526,971 | +1,798,126 | +18.5% | $293.0M | 6.7% | $25.4 |
| Q3 2025 | 9,728,845 | +228,845 | +2.4% | $156.8M | 4.4% | $16.1 |
| Q2 2025 | 9,500,000 | 0 | — | $152.0M | 4.9% | $16.0 |
| Q1 2025 | 9,500,000 | +3,500,000 | +58.3% | $162.4M | 5.3% | $17.1 |
| Q4 2024 | 6,000,000 | +1,652,536 | +38.0% | $148.6M | 5.6% | $24.8 |
| Q3 2024 | 4,347,464 | +1,463,728 | +50.8% | $123.9M | 4.0% | $28.5 |
| Q2 2024 | 2,883,736 | +2,390,384 | +484.5% | $76.1M | 2.3% | $26.4 |
| Q1 2024 | 493,352 | 506,648 | -50.7% | $15.9M | 0.5% | $32.3 |
| Q4 2023 | 1,000,000 | 1,797,955 | -64.3% | $42.1M | 1.5% | $42.1 |
| Q3 2023 | 2,797,955 | 2,623,375 | -48.4% | $107.4M | 4.2% | $38.4 |
| Q2 2023 | 5,421,330 | 2,011,387 | -27.1% | $102.8M | 4.8% | $19.0 |
| Q1 2023 | 7,432,717 | 2,277,283 | -23.5% | $115.3M | 4.9% | $15.5 |
| Q4 2022 | 9,710,000 | 150,246 | -1.5% | $172.4M | 7.5% | $17.8 |
| Q3 2022 | 9,860,246 | +405,246 | +4.3% | $55.0M | 2.7% | $5.6 |
| Q2 2022 | 9,455,000 | +2,230,387 | +30.9% | $36.9M | 2.5% | $3.9 |
| Q1 2022 | 7,224,613 | +2,449,613 | +51.3% | $39.8M | 2.6% | $5.5 |
| Q4 2021 | 4,775,000 | — | — | $40.7M | 3.0% | $8.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Deep Track Capital, LP first disclose a IMVT position in 13F-HR filings?
Deep Track Capital, LP first reported IMMUNOVANT INC (IMVT) on its 13F-HR filing for the period ending 2021-12-31 (Q4 2021). The position has appeared on 18 reported quarters within Pactolio's tracked window.
What was Deep Track Capital, LP's most recent quarter-over-quarter share-count change in IMVT?
Deep Track Capital, LP held the same 11,526,971 shares of IMVT between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Deep Track Capital, LP's cost basis in IMVT?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.